Latest / Doctor Drop It with Dr Barbara Hessel / I Examined Peptide Vials Patients Were Injecting (What I Found Concerns Me)

Transcript

I Examined Peptide Vials Patients Were Injecting (What I Found Concerns Me) · Doctor Drop It with Dr Barbara Hessel

• 0:00
  SPEAKER_00: Last month, a patient came in holding a vial.
• 0:02
  SPEAKER_00: She'd been injecting every day for three weeks.
• 0:06
  SPEAKER_00: When I asked her where she got it, she told me that her acupuncturist had recommended it.
• 0:10
  SPEAKER_00: The label said BPC 157.
• 0:13
  SPEAKER_00: Underneath that, four words, for research purposes only.
• 0:18
  SPEAKER_00: I examined the vial.
• 0:20
  SPEAKER_00: I couldn't honestly tell her with any confidence what was actually inside.
• 0:24
  SPEAKER_00: And that conversation is actually happening in my practice more than it ever has before.
• 0:30
  SPEAKER_00: Patients are ordering peptides online, injecting compounds bought from websites, and trusting that for research purposes only says something meaningful about what's in the product.
• 0:41
  SPEAKER_00: It doesn't say what they think it says.
• 0:44
  SPEAKER_00: Because if you've seen peptides like BPC 157 or TB500 on social media marketed for healing and recovery, this is what I want every patient to hear before they order anything.
• 0:56
  SPEAKER_00: I'm Dr.
• 0:56
  SPEAKER_00: Barbara Hessel, I'm board certified in obesity medicine.
• 1:00
  SPEAKER_00: My goal today is patient safety.
• 1:02
  SPEAKER_00: Specifically, two questions every woman considering these compounds deserves an honest answer to.
• 1:10
  SPEAKER_00: Whether what's in the vial is actually what the label says, and whether it's safe to inject at all.
• 1:16
  SPEAKER_00: So what peptides actually are?
• 1:19
  SPEAKER_00: You've heard of amino acids.
• 1:21
  SPEAKER_00: They're the building blocks of protein and the building blocks of peptides too.
• 1:26
  SPEAKER_00: Here's the simplest way to think about amino acids.
• 1:28
  SPEAKER_00: They're like individual LEGO grips, a few of them snack together, form a small structure called a peptide.
• 1:35
  SPEAKER_00: Hundreds or thousands of them connected and folded into a complex shape, become a protein.
• 1:40
  SPEAKER_00: Now peptides aren't new in medicine.
• 1:42
  SPEAKER_00: Insulin is a peptide, semaglutide, the active compound nozemphic is a peptide.
• 1:48
  SPEAKER_00: The difference is that those drugs went through rigorous manufacturing controls and clinical trials before they reached any patient.
• 1:56
  SPEAKER_00: The peptides circulating on social media started in bodybuilding and biohacking circles.
• 2:02
  SPEAKER_00: Now longevity influencers are marketing them to anyone with a website and a credit card.
• 2:07
  SPEAKER_00: BBC 157 for healing tendons and gut inflammation.
• 2:11
  SPEAKER_00: TD500 for soft tissue repair.
• 2:14
  SPEAKER_00: The list is longer than that, but the pattern is identical.
• 2:17
  SPEAKER_00: Each compound comes with a claim, and each claim comes with the word research attached to it.
• 2:23
  SPEAKER_00: Here's what that word actually means for research use only.
• 2:27
  SPEAKER_00: It's not a safety label.
• 2:29
  SPEAKER_00: Here's what most people don't know about the phrase for research purposes only.
• 2:34
  SPEAKER_00: It isn't a description of what the product is.
• 2:37
  SPEAKER_00: It's a legal disclaimer that protects the seller and places every bit of the liability on you.
• 2:43
  SPEAKER_00: When a company sells a compound labeled for research purposes only, they're technically not making a medical claim and they're technically not selling a drug for human use.
• 2:53
  SPEAKER_00: That label lets them operate outside FDA oversight.
• 2:56
  SPEAKER_00: They put the onus on the buyer.
• 2:59
  SPEAKER_00: If you inject and something goes wrong, the company has already covered itself.
• 3:03
  SPEAKER_00: You accepted the risk the moment you ordered.
• 3:06
  SPEAKER_00: I've seen patients who found these products through social media, bought them from a wellness clinic, and in one case got them from their acupuncturist.
• 3:14
  SPEAKER_00: None of these channels changed what the label actually means.
• 3:18
  SPEAKER_00: For research purposes only, is a legal construction and not a quality standard.
• 3:23
  SPEAKER_00: Here's reveal number two.
• 3:25
  SPEAKER_00: The research isn't what the marketing says it is.
• 3:28
  SPEAKER_00: The word research sounds like clinical proof.
• 3:31
  SPEAKER_00: BPC 157 has over 150 published papers.
• 3:35
  SPEAKER_00: That sounds like a substantial body of evidence, but here's what it actually is.
• 3:40
  SPEAKER_00: Go find a study that was shared with you about any of these peptides.
• 3:44
  SPEAKER_00: Look at the methods section.
• 3:45
  SPEAKER_00: If you see the words murine model or rack study anywhere in there, you're looking at animal data.
• 3:52
  SPEAKER_00: That's preclinical plausibility.
• 3:54
  SPEAKER_00: It means the compound showed a signal in a controlled animal environment.
• 3:58
  SPEAKER_00: It's a starting point for research, not an end point.
• 4:01
  SPEAKER_00: And it's not necessarily evidence that the compound is safe or effective in humans.
• 4:06
  SPEAKER_00: The strongest marketing right now surrounds what's being called the wolverine stack.
• 4:11
  SPEAKER_00: BPC 157 combined with TB500, sold together for tissue repair.
• 4:17
  SPEAKER_00: A 2026 sports medicine review looked specifically at this combination and found no human orthopedic data.
• 4:26
  SPEAKER_00: The FDA named both compounds out of its list of bulk drug substances that raise safety concerns.
• 4:33
  SPEAKER_00: The two reasons for safety concerns immune response risk and peptide-related contaminants for manufacturing.
• 4:40
  SPEAKER_00: An immune response means that your body treats the compound as a threat.
• 4:44
  SPEAKER_00: Physicians working with regulated peptides won't run them past 12 weeks before cycling off for exactly that reason.
• 4:52
  SPEAKER_00: These aren't inert substances.
• 4:54
  SPEAKER_00: They do real things inside your body.
• 4:56
  SPEAKER_00: The long-term data on what those things are in humans simply doesn't exist yet.
• 5:00
  SPEAKER_00: The regulatory picture is also shifting.
• 5:03
  SPEAKER_00: The FDA has scheduled an advisory committee meeting to examine whether compounds like BPC 157 and TB500 should be permitted for compounding access.
• 5:13
  SPEAKER_00: Part of what's driving this is the current administration's re-examination of prior restrictions.
• 5:19
  SPEAKER_00: Before February of 2024, some of these peptides were available through licensed compounding pharmacies under physician supervision with quality controls in place.
• 5:28
  SPEAKER_00: This is actually really important about where you're getting it from and whether there's quality controls in place.
• 5:34
  SPEAKER_00: The FDA expanded its bulk drug substances list that month and shut most of it down.
• 5:41
  SPEAKER_00: The door is now being re-examined to see if it should be reopened.
• 5:45
  SPEAKER_00: Retatrotide is a next generation weight loss compound currently in phase three clinical trials from Lilly.
• 5:52
  SPEAKER_00: The phase two data show that it works.
• 5:54
  SPEAKER_00: With the social media post skip over, is that 18% of the participants in phase two drop out due to side effects and the final study isn't complete.
• 6:04
  SPEAKER_00: Now, 18%, that's a lot of people.
• 6:06
  SPEAKER_00: That's one in five people dropping out from side effects.
• 6:09
  SPEAKER_00: But people are already buying it online anyway.
• 6:13
  SPEAKER_00: Have you come across a product with a label for research purposes only?
• 6:17
  SPEAKER_00: Drop what it was in the comments.
• 6:18
  SPEAKER_00: I'd love to see what's circulating.
• 6:20
  SPEAKER_00: Now, here's reveal number three.
• 6:22
  SPEAKER_00: Nobody can tell you what's in the vial.
• 6:25
  SPEAKER_00: I've examined vials that patients have brought in.
• 6:28
  SPEAKER_00: They usually arrive as a white powder in a small glass vial.
• 6:31
  SPEAKER_00: The patient mixes with bacteriostatic water and injects it themselves.
• 6:36
  SPEAKER_00: I can look at that vial, but I cannot tell you with any confidence what's actually inside.
• 6:41
  SPEAKER_00: At this point, the purity is unverifiable.
• 6:44
  SPEAKER_00: The dose listed might not match what's actually put in, and the compound named on the label might not be the compound that's inside.
• 6:53
  SPEAKER_00: And this is the part that marketing never addresses.
• 6:56
  SPEAKER_00: Companies are importing these products from unregulated labs overseas and sell them directly to consumers.
• 7:03
  SPEAKER_00: Independent testing has found that the amount of active compound in a vial often doesn't match what the label says.
• 7:09
  SPEAKER_00: Sometimes what's inside is a completely different substance from what's listed.
• 7:13
  SPEAKER_00: Contamination is a real clinical concern.
• 7:16
  SPEAKER_00: These products can carry heavy metals and bacterial endotoxins from manufacturing.
• 7:21
  SPEAKER_00: Now, injecting a contaminated compound can cause infections and abscesses.
• 7:27
  SPEAKER_00: In serious cases, contamination can cause sepsis, and there's reports meningitis.
• 7:32
  SPEAKER_00: We're also in what I describe as the wild, wild west of dosing.
• 7:37
  SPEAKER_00: Patients are guessing their doses from online forums.
• 7:40
  SPEAKER_00: Others are following protocols posted by influencers.
• 7:44
  SPEAKER_00: Influencers who aren't physicians and aren't doing blood work on the people they're advising.
• 7:49
  SPEAKER_00: There's no consistency, and there's no one checking how their body is actually responding.
• 7:54
  SPEAKER_00: I've had patients tell me they're stacking four or five compounds at once.
• 7:58
  SPEAKER_00: The few human studies that exist on these peptides were conducted on single agents.
• 8:03
  SPEAKER_00: There's no data on what happens when you combine them because no one has studied stacking regimens.
• 8:09
  SPEAKER_00: More factors affect the result, and the experiment gets harder to interpret the more compounds you add.
• 8:16
  SPEAKER_00: The patient is running a chemistry experiment on themselves with no controls and no one watching.
• 8:21
  SPEAKER_00: Please, let's face the truth.
• 8:23
  SPEAKER_00: You can't stack your way out of what's driving your hunger.
• 8:27
  SPEAKER_00: One thing I'd say directly to anyone considering peptides, even prescription peptides for weight loss.
• 8:34
  SPEAKER_00: Peptides won't solve what's happening with your hunger.
• 8:37
  SPEAKER_00: I've had patients come in who've been on four or five different compounds for months.
• 8:41
  SPEAKER_00: They've cycled protocols from forarms, they've researched every combination.
• 8:45
  SPEAKER_00: The hunger driving the eating is exactly where it was before any of it started.
• 8:50
  SPEAKER_00: The peptides don't touch the root cause because the hunger isn't a peptide deficiency.
• 8:56
  SPEAKER_00: It's a signal that's never been correctly identified or mapped to an approach built for it.
• 9:01
  SPEAKER_00: What I work on with women, I see, is identifying the hunger type that's been driving the eating.
• 9:07
  SPEAKER_00: Once that's matched to the right approach, the result holds.
• 9:10
  SPEAKER_00: Now no stack changes that equation.
• 9:13
  SPEAKER_00: You can't out-peptide a hunger pattern that's never been addressed at the source.
• 9:18
  SPEAKER_00: What the standard actually looks like.
• 9:20
  SPEAKER_00: If you're genuinely interested in peptide therapy and want to pursue it responsibly, here's the standard I'd apply.
• 9:27
  SPEAKER_00: Physician oversight and a prescription from a licensed provider filled through a compounding pharmacy that's GMP compliant.
• 9:35
  SPEAKER_00: GMP compliance means that regulatory requirements for production and quality control and also that they can provide a certificate of analysis from an independent lab.
• 9:45
  SPEAKER_00: A certificate of analysis is a document from a third-party lab that confirms that the peptide's purity and composition.
• 9:52
  SPEAKER_00: If a company can't provide one, that tells you something important about what they actually know about what they're selling.
• 9:59
  SPEAKER_00: Before any peptide conversation, I want to know what your blood work looks like and what's actually driving the problem you're trying to solve.
• 10:06
  SPEAKER_00: These compounds do real things inside your body.
• 10:09
  SPEAKER_00: They deserve the same care and attention you'd give any other medication that actually works.
• 10:14
  SPEAKER_00: The trend isn't slowing down.
• 10:16
  SPEAKER_00: More patients are going to come in holding bials that I can't identify.
• 10:19
  SPEAKER_00: I'd rather be honest about what the evidence shows and what I can verify than to point someone to a website and hope for the best.
• 10:27
  SPEAKER_00: The research doesn't mean what the marketing says it means.
• 10:31
  SPEAKER_00: If you're injecting something that you've mixed yourself from an unregulated lab, you're running an experiment on your own body.
• 10:37
  SPEAKER_00: No physician is watching, no one is tracking the result.
• 10:41
  SPEAKER_00: If you want to understand how to use a medication window to build something that actually holds, there's already a video on this channel that covers exactly that.
• 10:49
  SPEAKER_00: It's called The Way Comes Back After Ozempic unless you build these three things first.
• 10:55
  SPEAKER_00: Watch that one next.